Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
NCT05424029 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-07-03
Summary
The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.
Conditions
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
David Jones, MD · Memorial Sloan Kettering Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-14
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United States
Study Locations
More Related Trials
-
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT00293332 ·Status: TERMINATED ·Phase: PHASE2
-
Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC
NCT00250978 ·Status: COMPLETED ·Phase: PHASE1
-
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
NCT02350764 ·Status: COMPLETED ·Phase: PHASE2
-
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
NCT04227028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
NCT00702572 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT02259621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel
NCT00900172 ·Status: COMPLETED
-
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
NCT06800339 ·Status: RECRUITING ·Phase: PHASE1
-
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
NCT00290550 ·Status: TERMINATED ·Phase: PHASE2
-
Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer
NCT00003692 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
NCT00492206 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT01496742 ·Status: COMPLETED ·Phase: PHASE2
-
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00020202 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
NCT02031744 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
NCT00564876 ·Status: TERMINATED ·Phase: PHASE2
-
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03048500 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
NCT02276027 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02523469 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682 ·Status: RECRUITING ·Phase: PHASE2
-
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
NCT02054052 ·Status: COMPLETED ·Phase: PHASE2